menu
    • menu
    [{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JORDAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Immunology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"MS Pharma","sponsor":"Kashiv BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"MS Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"MS Pharma \/ MS Pharma","highestDevelopmentStatusID":"10","companyTruncated":"MS Pharma \/ MS Pharma"},{"orgOrder":0,"company":"MS Pharma","sponsor":"Polpharma Biologics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"POLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase III","graph3":"MS Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MS Pharma \/ MS Pharma","highestDevelopmentStatusID":"10","companyTruncated":"MS Pharma \/ MS Pharma"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JORDAN","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Extensively Hydrolyzed Formula","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JORDAN","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Extensively Hydrolyzed Formula","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JORDAN","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"Extensively Hydrolyzed Rice Protein Formula","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JORDAN","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Fiber","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JORDAN","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"New Extensively Hydrolysed Formula","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Delta Consultants","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JORDAN","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"New Infant Formula","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Delta Consultants","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Delta Consultants"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Axiodis CRO","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JORDAN","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"New Infant Formula","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Axiodis CRO","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Axiodis CRO"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JORDAN","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"New Thickened Formula","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Statitec","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JORDAN","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Rice","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Statitec","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Statitec"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JORDAN","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Thickened Infant Formula","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"MS Pharma","sponsor":"Polpharma Biologics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"POLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"MS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MS Pharma \/ MS Pharma","highestDevelopmentStatusID":"15","companyTruncated":"MS Pharma \/ MS Pharma"},{"orgOrder":0,"company":"MS Pharma","sponsor":"Klinge Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Protein","year":"2024","type":"Licensing Agreement","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"MS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MS Pharma \/ MS Pharma","highestDevelopmentStatusID":"15","companyTruncated":"MS Pharma \/ MS Pharma"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Slb Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JORDAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Slb Pharma","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Slb Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Munir Sukhtian group

    Menu

    Munir Sukhtian group

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MS Pharma

                            Jordan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MS Pharma

                            Jordan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vedolizumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Recipient : Polpharma Biologics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Polpharma and MS Pharma Sign Licensing Agreements for Proposed Biosimilars

                            Details : The agreement aims to commercialize its biosimilar candidates, vedolizumab (PB016), ocrelizumab (PB018), and guselkumab (PB019), in the MENA region.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            September 02, 2025

                            Lead Product(s) : Vedolizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Recipient : Polpharma Biologics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MS Pharma

                            Jordan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MS Pharma

                            Jordan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omalizumab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Recipient : Kashiv BioSciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Kashiv and MS Pharma Enter into MENA License and Supply Agreement for ADL-018

                            Details : MS Pharma will be responsible for the licensing, distribution, and commercialization of ADL-018, biosimilar candidate to Xolair (omalizumab), in the MENA region.

                            Product Name : ADL-018

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            August 05, 2025

                            Lead Product(s) : Omalizumab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Recipient : Kashiv BioSciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            United Pharmaceuticals

                            Jordan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            United Pharmaceuticals

                            Jordan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : New Infant Formula

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : Axiodis CRO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evolution of Functional Gastrointestinal Disorders in Infants Fed With a New Infant Formula

                            Details : New Infant Formula is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Gastrointestinal Diseases.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            July 05, 2024

                            Lead Product(s) : New Infant Formula

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : Axiodis CRO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            United Pharmaceuticals

                            Jordan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            United Pharmaceuticals

                            Jordan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Slb Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Tolerance, Efficacy and Safety of an Hydrolyzed Formula in Infants With IgE/Non-IgE Mediated CMA...

                            Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Milk Hypersensitivity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 01, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Slb Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            MS Pharma

                            Jordan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MS Pharma

                            Jordan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : Klinge Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            MS Pharma Partners for FYB203 Biosimilar Commercialization in MENA Region

                            Details : MS Pharma becomes a partner for the commercialization of FYB203, Formycon’s Biosimilar to Eylea® (Aflibercept), in the MENA Region for the treatment of neovascular age-related macular degeneration.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            May 14, 2024

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : Klinge Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            United Pharmaceuticals

                            Jordan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            United Pharmaceuticals

                            Jordan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : New Infant Formula

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : Delta Consultants

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Efficacy of a New Specific Infant Formula in Case of Functional Constipation

                            Details : New Infant Formula is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Constipation.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            April 22, 2022

                            Lead Product(s) : New Infant Formula

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : Delta Consultants

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            United Pharmaceuticals

                            Jordan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            United Pharmaceuticals

                            Jordan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fiber

                            Therapeutic Area : Dermatology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of an Adapted Formula on Atopic Dermatitis.

                            Details : Fiber is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            April 08, 2022

                            Lead Product(s) : Fiber

                            Therapeutic Area : Dermatology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            MS Pharma

                            Jordan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MS Pharma

                            Jordan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : Polpharma Biologics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Bioeq, the Polpharma Biologics Group Joint Venture Company and MS Pharma Sign Exclusive Agreement for Ranibizu...

                            Details : Under the exclusive agreement, MS Pharma will be responsible for the registration and commercialization of FYB201/CHS-201 (Ranibizumab), in the Middle East and North African countries. MS Pharma will start the registration procedures in MENA immediately.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            December 14, 2021

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : Polpharma Biologics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            United Pharmaceuticals

                            Jordan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            United Pharmaceuticals

                            Jordan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rice

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Statitec

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Hypoallergenicity of a New Formula Based on Hydrolyzed Rice Proteins

                            Details : Rice is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Cow Milk Allergy.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            June 15, 2018

                            Lead Product(s) : Rice

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Statitec

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            United Pharmaceuticals

                            Jordan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            United Pharmaceuticals

                            Jordan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Extensively Hydrolyzed Formula

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Hypoallergenicity of an Extensively Hydrolyzed Formula

                            Details : Extensively Hydrolyzed Formula is a Dietary Supplement drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cow Milk Allergy.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            March 17, 2016

                            Lead Product(s) : Extensively Hydrolyzed Formula

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth